

**AMENDMENTS TO THE CLAIMS**

**1. (Currently Amended)** A peptide selected from the group consisting of An  
~~epidermal growth factor receptor (EGFR) derived peptide which is capable of inducing a~~  
~~cytotoxic T lymphocyte and an antibody specific for said peptide, wherein the EGFR derived~~  
~~peptide consists of at least 8 consecutive amino acid residues derived from the amino acid~~  
~~sequence of~~ EGFR<sub>800-809</sub> (SEQ ID NO: 1), EGFR<sub>124-132</sub> (SEQ ID NO: 2), EGFR<sub>54-62</sub> (SEQ ID NO:  
3), EGFR<sub>479-488</sub> (SEQ ID NO: 4) or EGFR<sub>1138-1147</sub> (SEQ ID NO: 5).

**2-5. (Cancelled)**

**6. (Currently Amended)** A pharmaceutical composition comprising the peptide of  
Claim 1, for inducing a cytotoxic T lymphocyte<sub>2</sub> and an antibody specific for said peptide.

**7-19. (Cancelled)**